Donate Now
  • Research Ongoing
Inflammatory Arthritis from Cancer Immunotherapy: A Canada-Wide Study
Research_Inflammatory-Arthritis-from-Cancer-Immunotherapy_425x296
Scientific Study Title:
Gaining Insight into Immune Checkpoint Inhibitor Associated Inflammatory Arthritis Using Administrative Health Data
Start Date:
  • 2025
End Date:
  • 2029
Research Category
Tags
w4R-FYhKO3MDX_SNsFm0l-2HzrkmgyBACM3P7FfcSVs
Carrie Ye
Research Scientist, Rheumatology, MD, MPH, FRCPC
Marie Hudson- Website Headshot-400x400
Marie Hudson
Research Scientist, Rheumatology MD, MPH, FRCPC
TW1qxylx0zwYX9Q0ZyFNO-bWXOFBDE0-RFS9WVLkRtA
Shahin Jamal
Clinician Investigator, MD, FRCPC, MSc
37moj44c-PHhjix1YE98Y88x4tjwFQkV-ovNe1hfj-M
Janet Roberts
Clinician Investigator, MD, MPH, FRCPC

Ready to Participate?

Life-changing arthritis research is only possible with your help!
Participate Now

Why do this research?

Reason For Research

Immunotherapy is a powerful cancer treatment that helps the immune system fight cancer. Sometimes, immunotherapy can cause the immune system to mistakenly attack healthy parts of the body, such as the joints. This is known as immune checkpoint inhibitor induced inflammatory arthritis. Right now, we don’t know much about who gets inflammatory arthritis from immunotherapy, how common it is, or how to best treat or prevent it.

Canada has a unique advantage in studying this problem because it has a national database of confirmed cases of immune checkpoint inhibitor induced inflammatory arthritis. Understanding this better can help patients and doctors make safer, more informed decisions about cancer treatments.

Methodology

Execution of Research

First, we will figure out the best way to find cases of immune checkpoint inhibitor induced inflammatory arthritis using existing health records. We will then test these methods using confirmed cases from a specialized Canadian database. Once we know which method works best, we will use it to look at large groups of people across several provinces to see how common immune checkpoint inhibitor induced inflammatory arthritis is, who is most at risk, and what happens to those who get it.

Who is involved?

Involvement

Patients enrolled in the CanRIO database, as well as all individuals in five provinces (BC, AB, ON, QC, NS) who have been treated with immunotherapy for cancer.

How Are Equity, Diversity and Inclusion Addressed or Taken Into Consideration?

This study will allow us to understand immunotherapy-associated inflammatory arthritis at a population level, representing the full spectrum of disease across multiple provinces in Canada.

How Will/ Have Patients Contribute to This Research?

Patients from across Canada have generously consented to contribute their health information to the CanRIO database, enabling this crucial research to proceed. Patient partners have helped to shape the research questions and will be integral in knowledge dissemination efforts.

Related Research

Connecting Voices-PLS-715 x 405

Connecting Voices for Equitable Rheumatoid Arthritis Care Access

Read More
New Model of At-Home Follow-Up Care_PLS

A New Model of At-Home Follow-Up Care for Rheumatoid Arthritis

Read More
Ozempic-PLS-Feature-Image-425x296-1

Are medications like Ozempic safe and effective for people with inflammatory arthritis and type 2 diabetes?

Read More
2026-Studies-to-Watch-Decision-Aid

Evaluating a Decision Aid for Tapering Biologic Medications in Rheumatoid Arthritis

Read More
VIVA-Study-PLS-image

Virtual Intervention for Vertebral frActure (VIVA): A rehab program for better recovery after spine fractures

Read More
Other-Types-of-Arthritis-10.0-1

Improving quality of arthritis care for Indigenous populations

Read More